Literature DB >> 32493977

Development and deployment of an at-home strength and conditioning program to support a phase I trial in persons with chronic spinal cord injury.

Jennifer L Maher1,2, Kimberly D Anderson3, Katie L Gant4, Rachel E Cowan4,5.   

Abstract

STUDY
DESIGN: Nonrandomized clinical trial (NCT02354625).
OBJECTIVES: As a part of a Phase I clinical trial to assess the safety of autologous human Schwann cells (ahSC) in persons with chronic spinal cord injury (SCI), participants engaged in a multimodal conditioning program pre- and post-ahSC transplantation. The program included a home-based strength and endurance training program to prevent lack of fitness and posttransplantation detraining from confounding potential ahSC therapeutic effects. This paper describes development, deployment, outcomes, and challenges of the home-based training program.
SETTING: University-based laboratory.
METHODS: Development phase: two men with paraplegia completed an 8-week laboratory-based 'test' of the home-based program. Deployment phase: the first four (two males, two females) participant cohort of the ahSC trial completed the program at home for 12 weeks pre and 20 weeks post ahSC transplant.
RESULTS: Development phase: both participants improved their peak aerobic capacity (VO2peak) (≥17%), peak power output (POpeak) (≥8%), and time to exhaustion (TTE) (≥7%). Deployment phase: pretransplant training minimally increased fitness in the two male participants (≥6% POpeak and ≥9% TTE). The two women had no POpeak changes and slight TTE changes (+2.6 and -1.2%, respectively.) All four participants detrained during the posttransplant recovery period. After posttransplant retraining, all four participants increased TTE (4-24%), three increased VO2peak (≥11%), and two increased POpeak (≥7%).
CONCLUSIONS: Home-based strength and condition programs can be effective and successfully included in therapeutic SCI trials. However, development of these programs requires substantial content knowledge and experience.

Entities:  

Year:  2020        PMID: 32493977     DOI: 10.1038/s41393-020-0486-7

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  1 in total

1.  Identification and Management of Cardiometabolic Risk after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers.

Authors:  Mark S Nash; Suzanne L Groah; David R Gater; Trevor A Dyson-Hudson; Jesse A Lieberman; Jonathan Myers; Sunil Sabharwal; Allen J Taylor
Journal:  Top Spinal Cord Inj Rehabil       Date:  2018
  1 in total
  2 in total

1.  Phase 1 Safety Trial of Autologous Human Schwann Cell Transplantation in Chronic Spinal Cord Injury.

Authors:  Katie L Gant; James D Guest; Anne E Palermo; Aditya Vedantam; George Jimsheleishvili; Mary Bartlett Bunge; Adriana E Brooks; Kim D Anderson; Christine K Thomas; Andrea J Santamaria; Monica A Perez; Rosie Curiel; Mark S Nash; Efrat Saraf-Lavi; Damien D Pearse; Eva Widerström-Noga; Aisha Khan; W Dalton Dietrich; Allan D Levi
Journal:  J Neurotrauma       Date:  2021-05-03       Impact factor: 4.869

Review 2.  Future Perspectives in Spinal Cord Repair: Brain as Saviour? TSCI with Concurrent TBI: Pathophysiological Interaction and Impact on MSC Treatment.

Authors:  Paul Köhli; Ellen Otto; Denise Jahn; Marie-Jacqueline Reisener; Jessika Appelt; Adibeh Rahmani; Nima Taheri; Johannes Keller; Matthias Pumberger; Serafeim Tsitsilonis
Journal:  Cells       Date:  2021-10-30       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.